Castle biosciences expands evidence supporting the performance of its tissuecypher® barrett's esophagus test in predicting future development of esophageal cancer through multiple data presentations at ddw 2024

Friendswood, texas--(business wire)---- $cstl #barrettsesophagus--castle will share three abstracts related to its tissuecypher® test at ddw 2024.

CSTL Ratings Summary

CSTL Quant Ranking